Press Releases

Date	Title
February 2, 2022	UNITY Biotechnology Reports Granting of New Employment Inducement Award SOUTH SAN FRANCISCO, Calif. , Feb. 02, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from January 18, 2022 , through February 1, 2022 , the Compensation
January 4, 2022	UNITY Biotechnology Provides Program Updates and Anticipated Milestones for 2022 12-week safety and efficacy analysis from a Phase 2 study of UBX1325 in diabetic macular edema (DME) expected in first half 2022 and wet age-related macular degeneration (wet AMD) expected in the second half of 2022 Phase 2 study of UBX1325 in wet AMD to include comparison with aflibercept